Aspirin 325Mg side effects: what 710 FDA adverse event reports show
Drug class
Nonsteroidal Anti-inflammatory Drug, Platelet Aggregation Inhibitor
Who reports
710 reports · 73% serious · 73 with death outcome · 48% female
Used for
temporarily relieves minor aches and pains due to: headache muscle pain toothache menstrual pain colds minor pains of arthritis temporarily reduces fever
Boxed warning
None in the current label
Causality screen of the 4 strongest signals
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 5 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Hospice care | 9 | 27.0 14.1–51.7ROR 27.3 · χ² 200 / p 1e-45 | 25.4 EB05 13.9 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious PRR 27.5 | no trial data cached |
| Subdural haematoma | 7 | 14.4 6.9–30.1ROR 14.5 · χ² 74 / p 3e-18 | 11.4 EB05 4.8 · IC025 +1.6 3/3 methods agree | Not in label — unassessed | serious PRR 11.4 | no trial data cached |
| Product substitution issue | 19 | 9.8 6.3–15.2ROR 10.0 · χ² 141 / p 8e-33 | 8.7 EB05 5.6 · IC025 +2.2 3/3 methods agree | Reporting / coding artifact | serious PRR 13.8 | no trial data cached |
| Diabetic ketoacidosis | 6 | 7.4 3.3–16.4ROR 7.4 · χ² 27 / p 1e-7 | 5.1 EB05 2.5 · IC025 +0.9 3/3 methods agree | Not in label — unassessed | serious PRR 5.9 | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Product substitution issue | 19 | 9.8 6.3–15.2ROR 10.0 · χ² 141 / p 8e-33 | 8.7 EB05 5.6 · IC025 +2.2 3/3 methods agree | Reporting / coding artifact | serious PRR 13.8 | no trial data cached |
| Hospice care | 9 | 27.0 14.1–51.7ROR 27.3 · χ² 200 / p 1e-45 | 25.4 EB05 13.9 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious PRR 27.5 | no trial data cached |
| Subdural haematoma | 7 | 14.4 6.9–30.1ROR 14.5 · χ² 74 / p 3e-18 | 11.4 EB05 4.8 · IC025 +1.6 3/3 methods agree | Not in label — unassessed | serious PRR 11.4 | no trial data cached |
| Diabetic ketoacidosis | 6 | 7.4 3.3–16.4ROR 7.4 · χ² 27 / p 1e-7 | 5.1 EB05 2.5 · IC025 +0.9 3/3 methods agree | Not in label — unassessed | serious PRR 5.9 | no trial data cached |
| Subarachnoid haemorrhage | 4 | 11.6 4.4–30.7ROR 11.6 · χ² 29 / p 4e-8 | 6.8 EB05 2.5 · IC025 +0.6 3/3 methods agree | Not in label — unassessed | serious PRR 9.2 | no trial data cached |
| Therapy change | 4 | 12.3 4.6–32.6ROR 12.3 · χ² 31 / p 1e-8 | 7.2 EB05 2.6 · IC025 +0.7 3/3 methods agree | Reporting / coding artifact | serious n=1 | no trial data cached |
| Incorrect dose administered by device | 3 | 3.5 1.1–10.8ROR 3.5 · χ² 3 / p 0.038 | 2.6 EB05 1.0 · IC025 -0.7 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious n=1 | no trial data cached |
| Tendon rupture (torn tendon) | 3 | 7.2 2.3–22.1ROR 7.2 · χ² 10 / p 7e-4 | 4.0 EB05 1.5 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Not in label — unassessed | serious PRR 6.2 | no trial data cached |
| Gastric haemorrhage | 3 | 7.6 2.5–23.7ROR 7.7 · χ² 11 / p 4e-4 | 4.2 EB05 1.6 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Not in label — unassessed | serious PRR 6.3 | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Aspirin 325Mg?
In FDA FAERS, the most frequently co-reported reaction terms for Aspirin 325Mg are hospice care, subdural haematoma, diabetic ketoacidosis, subarachnoid haemorrhage, tendon rupture, gastric haemorrhage. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Aspirin 325Mg have an FDA boxed warning?
No. The FDA label retrieved for Aspirin 325Mg has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Aspirin 325Mg causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 26942d32-d6e6-464d-8fc4-ffd9806d3e62, effective 20250112; matched on
openfda.generic_name.exact:"ASPIRIN 325MG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 9 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.